Tag Archives: NASDAQ:AGIO

The CSO of Agios Pharma is Exercising Options

Today it was reported that the CSO of Agios Pharma (AGIO – Research Report), Scott Biller, exercised options to buy 7,218 AGIO shares at $2.33 a share, for a total transaction value of $16.82K. Following this transaction Scott Biller’s holding

Cowen & Co. Thinks Agios Pharma’s Stock is Going to Recover

Cowen & Co. analyst Chris Shibutani reiterated a Buy rating on Agios Pharma (AGIO – Research Report) yesterday. The company’s shares closed yesterday at $47.35, close to its 52-week low of $41.63. According to TipRanks.com, Shibutani is a 3-star analyst

Oppenheimer Reaffirms Their Hold Rating on Agios Pharma (AGIO)

In a report released today, Mark Breidenbach from Oppenheimer maintained a Hold rating on Agios Pharma (AGIO – Research Report). The company’s shares closed yesterday at $65.93. Breidenbach observed: “Tuesday, Agios received FDA Breakthrough Therapy Designation (BTD) for TIBSOVO in

Agios Pharma (AGIO) Gets a Buy Rating from Cowen & Co.

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Agios Pharma (AGIO – Research Report) today. The company’s shares opened today at $64.91. According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.1% and

Agios Pharma (AGIO) Received its Third Buy in a Row

After Piper Jaffray and Leerink Partners gave Agios Pharma (NASDAQ: AGIO) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Chris Shibutani reiterated a Buy rating on Agios Pharma today. The company’s

Oppenheimer Maintains a Hold Rating on Agios Pharma (AGIO)

Oppenheimer analyst Leah R. Cann maintained a Hold rating on Agios Pharma (AGIO – Research Report) today. The company’s shares opened today at $66.83. Cann said: “The updated data for AG-881 ongoing phase I study presented today include approximately three